Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of switching from ARB to sacubitril/valsartan on out-of-office blood pressure in advanced CKD
jRCT1031220149Recruiting
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sacubitril + valsartan in hypertension (HTN) and chronic kidney disease (CKD). Primary endpoint: Change in 24-hour mean systolic blood pressure by ABPM. Started Jun 2022; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT1031220149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220149.